Type 2 diabetes and CKD

Adults with CKD and type 2 diabetes ACR is 3mg /mmol or more Offer an angiotensin receptor blocker ( ARB ) or an angiotensin -converting enzyme ( ACE ) inhibitor -titrated to the highest dose that the person can tolerate

ACR is between 3 - 30 mg /mmol already taking an ARB or ACE which has been titrated to the highest licensed dose that they can tolerateAND they meet the criteria in market authorization including adequate renal reserve ie eGFR thresholds

ACR is over 30 mg /mmol already taking an ARB or ACE which has been titrated to the highest licensed dose that they can tolerate AND they meet the criteria in market authorization including adequate renal reserve ie eGFR thresholds

Consider an SGLT2 inhibitor in addition to the the ARB or ACE

Offer an SGLT2 inhibitor in addition to the the ARB or ACE

evidence shows that SGLT2 inhibitors reduce the risk of CKD progression , mortality and cardiovascular events in adults with CKD and type 2 diabetes in people with ACR > 30 - SGLT2s are likely to be both more effective and cost saving in people with ACR of 3 - 30 - SGLT2s are likely to...